141 related articles for article (PubMed ID: 37399238)
1. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C; Lemoinne S; Soret PA; Hansen B; Hirschfield G; Gulamhusein A; Montano-Loza AJ; Lytvyak E; Pares A; Olivas I; Eaton JE; Osman KT; Schramm C; Sebode M; Lohse AW; Dalekos G; Gatselis N; Nevens F; Cazzagon N; Zago A; Russo FP; Floreani A; Abbas N; Trivedi P; Thorburn D; Saffioti F; Barkai L; Roccarina D; Calvaruso V; Fichera A; Delamarre A; Sobenko N; Villamil AM; Medina-Morales E; Bonder A; Patwardhan V; Rigamonti C; Carbone M; Invernizzi P; Cristoferi L; van der Meer A; de Veer R; Zigmond E; Yehezkel E; Kremer AE; Deibel A; Bruns T; Große K; Wetten A; Dyson JK; Jones D; Dumortier J; Pageaux GP; de Lédinghen V; Chazouillères O; Carrat F;
Hepatology; 2024 Jan; 79(1):39-48. PubMed ID: 37399238
[TBL] [Abstract][Full Text] [Related]
2. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
5. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
[TBL] [Abstract][Full Text] [Related]
6. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
7. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].
Liu Y; Fan X; Shen Y; Men R; Guo Y; Yang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):930-936. PubMed ID: 37866948
[TBL] [Abstract][Full Text] [Related]
8. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
[TBL] [Abstract][Full Text] [Related]
9. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
11. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
[TBL] [Abstract][Full Text] [Related]
12. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
Yang C; Guo G; Li B; Zheng L; Sun R; Wang X; Deng J; Jia G; Zhou X; Cui L; Guo C; Zhou X; Leung PSC; Gershwin ME; Shang Y; Han Y
Hepatol Int; 2023 Feb; 17(1):237-248. PubMed ID: 36309918
[TBL] [Abstract][Full Text] [Related]
13. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
[TBL] [Abstract][Full Text] [Related]
14. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
16. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
de Veer RC; Harms MH; Corpechot C; Thorburn D; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lammers WJ; Hansen BE; van Buuren HR; van der Meer AJ;
Aliment Pharmacol Ther; 2022 Nov; 56(9):1408-1418. PubMed ID: 36138566
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
18. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
[TBL] [Abstract][Full Text] [Related]
19. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
